
Scholar Rock Wins First FDA Nod
The FDA approved Scholar Rock therapy Isembyld to treat spinal muscular atrophy in adults and children. The injectable treatment marks the company's first regulatory approval and shares rose over twenty percent.
Xurve View
Insights:
Xurve View

Scholar Rock Holding Corp secured FDA approval for its muscle-targeting therapy Isembyld to treat spinal muscular atrophy, driving shares up 23% in after-market trading. The decision marks the first regulatory clearance for the company in a market estimated to affect 10,000 patients in the United States. Analysts project the treatment will reach $2.1 billion in worldwide peak sales by 2035.








